<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05064852</url>
  </required_header>
  <id_info>
    <org_study_id>HMPL-012-RWS-BTC101</org_study_id>
    <nct_id>NCT05064852</nct_id>
  </id_info>
  <brief_title>A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma</brief_title>
  <official_title>A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-arm, open-label,multi-center, observational real-world clinical&#xD;
      study to observe and evaluate the efficacy and safety of Surufatinib in the treatment of&#xD;
      patients with biliary tract cancer (BTC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-arm, open-label,multi-center, observational real-world clinical&#xD;
      study to observe and evaluate the efficacy and safety of Surufatinib in the treatment of&#xD;
      patients with biliary tract cancer (BTC). About 200 subjects are prepared to recruit in the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>6 months after the last patient enrolled</time_frame>
    <description>PFS was defined as the length of time from the administration of the first-dose until disease progression or death from any cause before disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safty</measure>
    <time_frame>up to 4 weeks after the last dose</time_frame>
    <description>The rate of AE and SAE in patients with BTC receiving surufatinib,AEs/SAEs were evaluated using NCI-CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>6 months after the last patient enrolled</time_frame>
    <description>DCR was defined as the percentage of patients with complete response (CR), partial response (PR) and stable disease (SD) according to Response Evaluation Criteria in Solid Tumours (RECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6 months after the last patient enrolled</time_frame>
    <description>OS was defined as the length of time from the administration of the first-dose until death from any cause.&#xD;
or lost of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>6 months after the last patient enrolled</time_frame>
    <description>ORR was defined as the percentage of patients with complete response (CR) and partial response (PR) according to Response Evaluation Criteria in Solid Tumours (RECIST).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>QoL</measure>
    <time_frame>6 months after the last patient enrolled</time_frame>
    <description>Using quality of life questionnaire (EORTC QLQ-C30) to collect the score. Scale range is 30~126, higher values are considered to be a better outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers</measure>
    <time_frame>before the first dose</time_frame>
    <description>Explore the correlation between curative effect and different biomarkers, such as EGFR mutation, FGFR etc.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Biliary Tract Carcinoma</condition>
  <arm_group>
    <arm_group_label>Surufatinib</arm_group_label>
    <description>Patients with BTC visited the site from 2021 to 2023 and received Surufatinib therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib</intervention_name>
    <description>The study is a real-world study. According to the actual medical history of patients, the usage of Surufatinib was collected.</description>
    <arm_group_label>Surufatinib</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Biliary Tract Carcinoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18, male or female;&#xD;
&#xD;
          2. Patients with histologically or cytologically confirmed unresectable or metastatic&#xD;
             BTC, including intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma&#xD;
             (EHCC), and gallbladder cancer (GBC); Surgical resection with positive margins are&#xD;
             allowed;&#xD;
&#xD;
          3. ECOG score 0-2;&#xD;
&#xD;
          4. Expected survival of ≥12 weeks;&#xD;
&#xD;
          5. Confirmed measurable (or evaluable) lesions that meet the requirements of RECIST 1.1;&#xD;
&#xD;
          6. It is not less than 7 days since the end of the last systematic treatment, and the&#xD;
             palliative treatment of the limited area is allowed&#xD;
&#xD;
             Treatment has been over 4 weeks;&#xD;
&#xD;
          7. The function of major organs and bone marrow was basically normal;&#xD;
&#xD;
          8. Fully understand this study, voluntarily participate in it, and sign the informed&#xD;
             consent.&#xD;
&#xD;
          9. Fertile male or female patients shall volunteer to use effective contraceptive&#xD;
             methods, such as double barrier contraception, condoms, oral or injected&#xD;
             contraceptives, and intrauterine devices, during the study period and within 90 days&#xD;
             after the last dosing of the investigational drug. All-female patients will be&#xD;
             considered fertile unless they have had natural menopause, or artificial menopause, or&#xD;
             sterilization (such as hysterectomy, bilateral adnexectomy, or ovarian radiation)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Fine basal skin that has been diagnosed with other malignant tumors within the past 5&#xD;
             years and has been effectively treated (Except for cell carcinoma, squamous cell&#xD;
             carcinoma of the skin, or in situ cervical cancer and breast cancer after effective&#xD;
             resection outside);&#xD;
&#xD;
          2. Receiving other investigational drugs or approved or under development antitumor&#xD;
             therapies;&#xD;
&#xD;
          3. Patients with contraindications to Surufatinib (e.g., active bleeding, ulcers,&#xD;
             intestinal perforation, bowel)Obstruction, medically uncontrolled hypertension, grade&#xD;
             III-IV cardiac dysfunction, major surgery within 30 days, severe liver and kidney&#xD;
             insufficiency, etc.);&#xD;
&#xD;
          4. The patient has any current disease or condition that affects the absorption of the&#xD;
             drug, or the patient cannot take it orally Surufatinib;&#xD;
&#xD;
          5. Demonstrated allergy to any component of the test drug and/or its excipients;&#xD;
&#xD;
          6. Pregnant (positive pregnancy test before dosing) or breast-feeding women;&#xD;
&#xD;
          7. Patients with large pleural effusion or ascites requiring drainage;&#xD;
&#xD;
          8. Taken a drug containing hyperforin perforatum within 3 weeks prior to the first study,&#xD;
             or before taken other CYP3A4 strong inducer or inhibitor within 2 weeks;&#xD;
&#xD;
          9. The investigator determined that liver metastases accounted for 50% or more of the&#xD;
             total volume of the liver;&#xD;
&#xD;
         10. Clinically intervened biliary obstruction was not in remission or required&#xD;
             anti-infective therapy as determined by the investigator 14 days prior to the first&#xD;
             study drug treatment;&#xD;
&#xD;
         11. Previous liver transplantation;&#xD;
&#xD;
         12. Clinically significant electrolyte abnormalities as determined by the investigator;&#xD;
&#xD;
         13. Any other diseases with clinically significant metabolic abnormalities, abnormal&#xD;
             physical observations, or abnormal laboratory findings, which are judged by the&#xD;
             investigator as evidence that the patient has a disease or condition that is&#xD;
             unsuitable for the study drug (e.g., epileptic seizures requiring treatment), or that&#xD;
             would interfere with the interpretation of the study results, or that may put the&#xD;
             patient at high risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yunfei Xu, M.D.</last_name>
    <phone>18560083735</phone>
    <email>xuyunfei1988@126.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

